NuCana PLC (NCNA)
1.59
+0.05
(+3.25%)
USD |
NASDAQ |
Nov 04, 16:00
1.64
+0.05
(+3.14%)
After-Hours: 20:00
NuCana Research and Development Expense (Annual): 31.19M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 31.19M |
| December 31, 2022 | 45.11M |
| December 31, 2021 | 50.67M |
| December 31, 2020 | 33.24M |
| December 31, 2019 | 25.19M |
| Date | Value |
|---|---|
| December 31, 2018 | 22.48M |
| December 31, 2017 | 22.82M |
| December 31, 2016 | 10.71M |
| December 31, 2015 | 8.642M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
25.19M
Minimum
2019
50.67M
Maximum
2021
37.08M
Average
33.24M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Adaptimmune Therapeutics PLC | 126.51M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 17.22M |
| Autolus Therapeutics PLC | 130.48M |
| Mereo BioPharma Group PLC | 17.42M |